Wednesday, March 10, 2010
"The source for European pharmaceutical biotechnology news..."
Why the rise of generics could mean a new game plan for the industry; plus Nycomed's leap into the big time.
Sponsors
Platinum Sponsors
Blog
Where our team of editors discuss what they think about the current NGP US Issues.
Marie Shields
Editor NGP Europe
Editor NGP Europe
Tough competition
The battle between generics and branded products has been going on for a long time: the claims and counter claims over Aspirin, for example, have been in process since the early 20th century.05 Aug 2009
You need adobe flash player to view this content
Latest News
-
Roche suspends drug development
Swiss-based pharmaceutical giant Roche have confirmed that, along with their partner Biogen Idec, they are to suspend the development of their late-stage rheumatoid arthritis...Read more
09/03/2010 18:11
Comments -
EU research sequences human gut microbe ...
A new study by EU-funded researchers sheds new light on the influence that microbes in our guts have on our health and could lead to the development of new treatments and...Read more
08/03/2010 07:50
Comments -
AstraZeneca reveals cutback details
This week has seen AstraZeneca make good on previously-announced plans to cuts as many as 8000 jobs worldwide by confirming the closure of a plant in Leicestershire, UK. The...Read more
04/03/2010 15:54
Comments -
Homeopathy: hard to swallow?
MPs have argued that spending money on homeopathy is a waste of NHS money and that the money should go to other areas. The House of Commons Science and Technology Committee have...Read more
03/03/2010 15:10
Comments -
Experts advise WHO, 'pandemic yet to peak'
The director-general of the World Health Organisation has today said that it is too early to declare that the peak of the global swine flu pandemic is over. WHO chief Margaret...Read more
24/02/2010 13:28
Comments -
Merck post earnings, shares fall
Despite posting a decent set of figures for the fourth quarter of 2009 this morning, Merck KGaA have missed analysts estimates, and, as such, have seen a slump in shares.Read more
23/02/2010 16:15
Comments
Editor’s Choice
-
The push of pharmaceutical research and develop...
With patent expiries due on some of the industry's biggest-selling drugs, pharmaceutical research and development has never been so important to the industry. What's more, in...Read more -
Are blockbuster drugs dead in the water?
Reports suggest that blockbuster drugs - defined as a drug that generates more than $1 billion of revenue each year - are beginning to wane. Are the reports true? And if so, how...Read more -
EFPIA fights back at counterfeit drugs
With counterfeit drugs becoming a very real problem for the pharmaceutical industry, EFPIA has announced Swedish trials of a new system aimed at combating the growth of this...Read more -
Changing times
Wyeth’s Thorir Bjornsson talks to NGP about dealing with attrition, the fallout from the merger with Pfizer, and what the future holds for the industry.Read more -
Bringing drug discovery into focus
GSK’s Anne Phillips offers a clear picture of transparency, bringing benefits to patients and the challenges of carrying out clinical trials in a global environment.Read more -
Trials and tribulations
Boehringer Ingelheim’s John Smith tells NGP about the importance of accountability in the pharmaceutical industry and the responsibilities of behaviour when a trial doesn’t...Read more
Readers’ Choice
-
Process excellence in master data manage...
It makes sense to analyze and ensure that the foundations of master data governance are solid and provide the business with strong processes to manage and share master data...Read more -
End-to-end clinical trials supply manage...
Stakeholders point to the clinical costs as a barrier to innovation. The FDA has confirmed in its “Critical path report” that “Streamlining Clinical Trials” is one of the key...Read more -
Imaging is key to success in oncology tr...
As defined by the NCI, "Translational research transforms scientific discoveries arising from laboratory, clinical, or population studies into clinical applications to reduce...Read more -
Emerging importance of health economics ...
Jacco Keja, Managing Director and Practice Leader at Quintiles Consulting, Visiting Professor Life Sciences Pricing, Erasmus University, looks at the emerging opportunities for...Read more -
Riding the wave
The global pharmaceutical industry is facing some tough challenges at the moment: patent expiries, a lack of new blockbusters, and now the ongoing crisis in the financial...Read more -
Building a sustainable biotech business ...
By Willem van Leeuwen – Managing Director QMR TechnologyRead more
Executive Interviews
Starting at phase zero
Michael Butler of Xceleron looks at the value a microdose study adds to a drug development programme.
Read more
The future of biomarker assays
Ralph McDade of Rules Based Medicine explains why more is better when it comes to data used to identify meaningful biomaker patterns.
Read more
Medical communications in a changing world
Amanda Smith of Caudex Medical explains the effects of the movement towards evidence-based medicine.
Read more
NGP Europe Summit: Drug Discovery
1st - 3rd September 2010
The Next Generation Drug Discovery Summit Europe is designed to bridge the growing technological gap between drug discovery and drug development.
Source: www.ngpharma.eu.com© 2010 GDS Publishing Ltd. All rights reserved.